‘Discontinuation Of Therapy in Multiple Sclerosis’ selected as JAMA Editor’s Choice: Clinical Trial of 2025The study Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis has been selected by the Editor of JAMA Neurology as an Editor’s Choice: Clinical Trials of 2025. This is a special honor for principal investigator and neurologist Eva Strijbis, PhD candidates Wing Hee Fung and Eline Coerver, and the rest of the research team at the MS Center Amsterdam.
National INFECT-TT program invests 7 million in accelerated clinical product development for infectious diseasesIn May 2026, the national valorisation programme InFECT-TT, under the umbrella of the InFECT-NL, will officially launch, together with the Infectious Diseases Innovation Fund (IDIF). InFECT-NL supports the clinical development of vaccines and therapies against infectious diseases and strengthens the pandemic preparedness of the Netherlands.
